This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
Save the date for next year!
March 18–20, 2024 | Barcelona, Spain

Josua Jordi
Chief Executive Officer at EraCal


Josua Jordi is the CEO and co-founder of EraCal Therapeutics and is in charge of the vision, execution & lead of EraCal since its inception. EraCal develops a novel oral-active anti-obesity drug with superior efficacy & tolerability. An ambitious team with world-class advisors leads the development of this first-in-class appetite suppressor, called Era-379, based on a new mechanism of action. Josua is a trained biochemist from ETH Zurich and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University. The platform forms the basis of a research collaboration with Novo Nordisk and Nestlé Health Science.

Agenda Sessions

  • The obesity marketplace is heating up


Speakers at this event